What is the recommended dosing of cefazolin for a pediatric patient with an open fracture?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cefazolin Dosing for Pediatric Open Fractures

Recommended Antibiotic Regimen

For pediatric patients with open fractures, administer cefazolin 25–50 mg/kg/day IV divided into 3–4 equal doses for mild-to-moderate injuries, or up to 100 mg/kg/day (maximum 12 g/day) for severe open fractures. 1

Dosing by Fracture Severity

  • Type I and Type II open fractures (Gustilo-Anderson): Cefazolin 25–50 mg/kg/day IV divided every 6–8 hours is appropriate for most cases. 1

  • Type III open fractures: Increase to cefazolin 100 mg/kg/day IV (maximum 12 g/day) divided every 6–8 hours, plus add gram-negative coverage with an aminoglycoside (gentamicin) or a third-generation cephalosporin. 2, 3

  • Penicillin allergy: Substitute clindamycin 10–13 mg/kg/dose IV every 6–8 hours. 4, 5, 6

Timing and Duration

  • Administer the first dose as soon as possible—ideally within 1 hour of presentation to the emergency department—to minimize infection risk. 2, 3, 6

  • Continue prophylactic antibiotics for 24–72 hours postoperatively (or until definitive wound closure), not beyond unless there is proven infection. 3

  • For Type I open fractures managed non-operatively, a protocol of 4 total doses of IV cefazolin (one in the ED, then three additional doses over 24 hours) has been shown safe and effective without oral antibiotics at discharge. 7


Practical Dosing Examples

Using the FDA-approved pediatric dosing table for cefazolin 1:

Weight (kg) 25 mg/kg/day ÷ q8h 50 mg/kg/day ÷ q8h 100 mg/kg/day ÷ q8h (severe)
10 kg 40 mg q8h 75 mg q8h 150 mg q8h
20 kg 75 mg q8h 150 mg q8h 300 mg q8h
30 kg 115 mg q8h 225 mg q8h 450 mg q8h
40 kg 150 mg q8h 300 mg q8h 600 mg q8h
50 kg 190 mg q8h 375 mg q8h 750 mg q8h

1


Key Clinical Considerations

Fracture Classification Drives Antibiotic Selection

  • Type I/II: Cefazolin monotherapy covers the primary pathogens (S. aureus, streptococci). 2, 6

  • Type III (especially IIIB/IIIC): Add gram-negative coverage because of higher contamination risk and soft-tissue injury. The 2023 AAOS guideline strongly recommends cefazolin plus an aminoglycoside or third-generation cephalosporin for Type III injuries. 2

  • Soil or water contamination: Consider broader coverage (e.g., add gentamicin or switch to ceftriaxone plus vancomycin per local protocols). 6, 8

Pharmacokinetic Data Support Standard Dosing

  • Recent pharmacokinetic studies in pediatric surgical patients confirm that weight-based cefazolin dosing achieves adequate tissue concentrations at fracture sites, with sustained levels above the MIC for S. aureus throughout the dosing interval. 9, 10, 11

  • For children ≥50 kg, a fixed 2-g dose is appropriate; for 25–50 kg, use 1 g per dose. 9, 10

Common Pitfalls to Avoid

  • Do not delay antibiotics waiting for operative debridement—early administration (within 1 hour) is critical to reducing deep infection rates. 2, 3, 6

  • Do not continue prophylactic antibiotics beyond 72 hours unless infection is documented; prolonged courses increase resistance and adverse effects without added benefit. 3

  • Do not omit gram-negative coverage for Type III fractures—the AAOS guideline emphasizes this addition for severe injuries. 2

  • Ensure adequate redosing intraoperatively if the procedure exceeds 2 hours or if there is significant blood loss (>1500 mL), to maintain therapeutic levels during surgery. 1

Renal Impairment Adjustments

  • In pediatric patients with mild-to-moderate renal impairment (CrCl 40–70 mL/min), give 60% of the normal daily dose divided every 12 hours. 1

  • For moderate impairment (CrCl 20–40 mL/min), reduce to 25% of the normal daily dose every 12 hours. 1

  • For severe impairment (CrCl 5–20 mL/min), give 10% of the normal daily dose every 24 hours after an initial loading dose. 1


Institutional Protocol Variability

  • A 2025 survey of Level I Pediatric Trauma Centers found near-complete consensus (93–100%) on cefazolin for Type I/II fractures and clindamycin for penicillin-allergic patients, but minimal consensus on Type III regimens and contamination scenarios. 6

  • Despite formal protocols at 88% of surveyed centers, only 47% achieved >80% compliance with the 1-hour antibiotic administration target, highlighting the need for quality improvement initiatives. 6


Summary Algorithm

  1. Assess fracture type (Gustilo-Anderson classification) and contamination.
  2. Administer cefazolin within 1 hour:
    • Type I/II: 25–50 mg/kg/day ÷ q6–8h
    • Type III: 100 mg/kg/day ÷ q6–8h plus gentamicin or ceftriaxone
  3. Redose intraoperatively if surgery >2 hours or major blood loss.
  4. Continue for 24–72 hours postoperatively (or until wound closure).
  5. Adjust for renal impairment if present.
  6. Switch to clindamycin if penicillin allergy documented.

2, 3, 1, 6

References

Guideline

aaos clinical practice guideline summary: prevention of surgical site infection after major extremity trauma.

The Journal of the American Academy of Orthopaedic Surgeons, 2023

Research

A protocol for the management of pediatric type I open fractures.

Journal of children's orthopaedics, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.